FTC Sepracor Inquiry Suggests New Antitrust Thrust: Evergreen Deals
Executive Summary
The Federal Trade Commission review of the Lilly/Sepracor agreement to develop (R)-fluoxetine suggests that FTC's interest in potential anti-generic strategies is expanding beyond abuse of process into corporate liaisons and development deals.
You may also be interested in...
AstraZeneca Nexium Marketing Draws FTC Scrutiny; DoJ Looking At Prilosec
The Federal Trade Commission is investigating AstraZeneca's marketing of the omeprazole follow-on product Nexium
AstraZeneca Nexium Marketing Draws FTC Scrutiny; DoJ Looking At Prilosec
The Federal Trade Commission is investigating AstraZeneca's marketing of the omeprazole follow-on product Nexium
Lilly/Sepracor Prozac Agreement Suggests Limits Of FTC Patent Inquiries
The Federal Trade Commission's approval of Lilly and Sepracor's (R)-fluoxetine agreement suggests that the agency's recent concern with patent defense strategies will not extend to evergreen deals.